Literature DB >> 1658305

Increased analgesic potency of mu agonists after continuous naloxone infusion in rats.

C A Paronis1, S G Holtzman.   

Abstract

Chronic opioid antagonist administration increases opioid binding sites and potentiates behavioral responses to morphine. The present study was designed to examine in rats the temporal and dosage parameters of naloxone-induced potentiation of morphine analgesia and the effect of continuous infusion of naloxone on the analgesic potency of other mu agonists. Cumulative dose-response curves were generated in a tail-flick procedure for each drug tested. Naloxone-filled osmotic pumps were then implanted s.c. for 1 week after which the rats were retested with the agonist. The potency ratio of morphine (ED50 before naloxone/ED50 after naloxone) showed orderly increases over a range of naloxone doses (0.03-1.0 mg/kg/hr) and increased, then decreased, over a range of time points (6-72 hr) after removal of the osmotic pumps. The relative potency of morphine was 2.1 at 24 hr after a 7-day infusion of 0.3 mg/kg/hr of naloxone. These parameters were then used in tests of other mu agonists. Five drugs produced maximum increases in tail-flick latencies before naloxone. Of these, naloxone increased the analgesic potency of fentanyl, methadone and levorphanol (relative potencies ranged from 1.7-2.1) but not of etorphine and propoxyphene. The naloxone infusion increased the maximum analgesic effect of meperidine, profadol and pentazocine, but had no effect on the analgesic activity of buprenorphine, butorphanol, ethylketocyclazocine and nalbuphine. Our results demonstrate that 7-day naloxone infusion increases the analgesic potency of some, but not all, opioids with mu agonist activity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1658305

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  15 in total

1.  Buprenorphine and opioid antagonism, tolerance, and naltrexone-precipitated withdrawal.

Authors:  Carol A Paronis; Jack Bergman
Journal:  J Pharmacol Exp Ther       Date:  2010-11-04       Impact factor: 4.030

2.  Effects of μ-opioid receptor agonists in assays of acute pain-stimulated and pain-depressed behavior in male rats: role of μ-agonist efficacy and noxious stimulus intensity.

Authors:  Ahmad A Altarifi; Kenner C Rice; S Stevens Negus
Journal:  J Pharmacol Exp Ther       Date:  2014-11-18       Impact factor: 4.030

3.  Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice.

Authors:  P Popik; E Kozela; A Pilc
Journal:  Br J Pharmacol       Date:  2000-07       Impact factor: 8.739

4.  Social and environmental influences on opioid sensitivity in rats: importance of an opioid's relative efficacy at the mu-receptor.

Authors:  Mark A Smith; Kara A Chisholm; Paul A Bryant; Jennifer L Greene; Jacob M McClean; William W Stoops; David L Yancey
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

5.  μ-Opioid receptor inhibition of substance P release from primary afferents disappears in neuropathic pain but not inflammatory pain.

Authors:  W Chen; J A McRoberts; J C G Marvizón
Journal:  Neuroscience       Date:  2014-02-26       Impact factor: 3.590

6.  Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity.

Authors:  Jianren Mao; Backil Sung; Ru-Rong Ji; Grewo Lim
Journal:  J Neurosci       Date:  2002-09-15       Impact factor: 6.167

7.  Individual differences in locomotor reactivity to a novel environment and sensitivity to opioid drugs in the rat. II. Agonist-induced antinociception and antagonist-induced suppression of fluid consumption.

Authors:  David A White; Mikhail Kalinichev; Stephen G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  2004-07-02       Impact factor: 4.530

8.  Sensitization and tolerance to the discriminative stimulus effects of mu-opioid agonists.

Authors:  C A Paronis; S G Holtzman
Journal:  Psychopharmacology (Berl)       Date:  1994-05       Impact factor: 4.530

9.  A mechanistic model for the sex-specific response to nalbuphine and naloxone in postoperative pain.

Authors:  Smita Kshirsagar; Robert Gear; Jon Levine; Davide Verotta
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-10-18       Impact factor: 2.745

10.  Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial.

Authors:  Sandra D Comer; Maria A Sullivan; Elmer Yu; Jami L Rothenberg; Herbert D Kleber; Kyle Kampman; Charles Dackis; Charles P O'Brien
Journal:  Arch Gen Psychiatry       Date:  2006-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.